Medifast outlines 2025 priorities with plans for $15M-$20M cost savings and new product expansions

Q4 2024 Management View CEO Dan Chard highlighted that 2024 was a transformative year for Medifast due to the increasing adoption of GLP-1 weight loss medications. The company is adapting to these ...
Nasdaq

Medifast's Q3 Loss Wider Than Expected, Sales Decline 36% Y/Y

Medifast, Inc. (MED) delivered third-quarter 2025 results, with the top line surpassing the Zacks Consensus Estimate while the bottom line missing the same. Both the metrics showed a year-over-year ...